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The CATERPILLER (CLR/NLR) gene family encodes a family of
putative nucleotide-binding proteins important for host defense.
Although nucleotide binding is thought to be central to this family,
this aspect is largely unstudied. The CATERPILLER protein
cryopyrin/NALP3 regulates IL-1 processing by assembling the
multimeric inflammasome complex. Mutations within the exon
encoding the nucleotide-binding domain are associated with he-
reditary periodic fevers characterized by constitutive IL-1 produc-
tion. We demonstrate that purified cryopyrin binds ATP, dATP, and
ATP-agarose, but not CTP, GTP, or UTP, and exhibits ATPase
activity. Mutation of the nucleotide-binding domain reduces ATP
binding, caspase-1 activation, IL-1 production, cell death, macro-
molecular complex formation, self-association, and association
with the inflammasome component ASC. Disruption of nucleotide
binding abolishes the constitutive activation of disease-associated
mutants, identifying nucleotide binding by cryopyrin as a potential
target for antiinflammatory pharmacologic intervention.
inflammation  IL-1
Mammalian genes encoding proteins with a conservednucleotide-binding domain (NBD) and a leucine-rich re-
gion (LRR) have received much attention of late. This gene
family known as CATERPILLER [for CARD, transcription
enhancer, R(purine)-binding, pyrin, lots of leucine repeats, also
CLR], NOD-LRR (for nucleotide-oligomerization domain), or
NLR (for NACHT-LRR, soon to be renamed NBD-LRR)
consists of 20 members (1–3). These proteins share structural
similarity with a subfamily of plant disease resistance (R)
proteins that mediate plant immunity to a wide array of micro-
bial pathogens and environmental insults (4). Several of these
genes have strong genetic association with human diseases.
Among these, the CIAS1 (for cold induced autoinflammatory
syndrome 1) gene is associated with three dominantly inherited
periodic fevers: familial cold autoinf lammatory syndrome
(FCAS), Muckle–Wells syndrome, and neonatal-onset multisys-
temic autoinflammatory disease (5). All three syndromes are
characterized by increased serum IL-1, and anti-IL-1 therapy
is the mainstay of treatment (6). The majority of known disease-
associated mutations reside in the NBD, although not in residues
predicted to directly interact with nucleotide (7).
Recent studies using CIAS1/ mice indicate that cryopyrin is
pivotal to the elaboration of IL-1 by macrophages in response
to bacterial RNA, certain Gram-positive bacteria, uric acid and
calcium pyrophosphate crystals, cellular toxins, and some Toll-
like receptor agonists (8–12). In vitro, cryopyrin assembles with
two CARD domain-containing adapter proteins, ASC/TMS1
and Cardinal/TUCAN/CARD8, as well as caspase-1 (the pro-
tease that cleaves pro-IL-1 to its mature form) to form a large
IL-1-converting holoenzyme known as the inflammasome (13).
Periodic fever-associated mutations in cryopyrin are thought to
cause constitutive inflammasome assembly. Additionally, WT
and disease-associated mutant cryopyrin induce cell death when
overexpressed (14, 15).
Although cryopyrin contains a consensus NBD that is postu-
lated to be crucial in the protein’s activity, the identity of the
bound nucleotide and the role of nucleotide binding in cryopyrin
function remain unexplored. Apoptotic protease activating
factor-1, Apaf-1, shares a similar but distinct NBD with
cryopyrin. Apaf-1 binds several adenosine-based nucleotides in
vitro, and recombinant Apaf-1 isolated from eukaryotic cells is
bound to dATP in its basal state (16, 17). Although the in vitro
caspase-3 activating activity of Apaf-1 requires dATP, there are
few detailed studies of nucleotide binding by CATERPILLER
family members. A bacterially expressed partially purified NBD
of CARD12 (Ipaf/Clan) exhibits ATP-binding activity (18).
CIITA, the founding member of the CATERPILLER family, is
associated with GTP when the protein is enriched from mam-
malian cells (19). The analysis of nucleotide binding by purified,
full-length CATERPILLER family members has been techni-
cally difficult and remains unexplored.
We now show the successful isolation of recombinant
cryopyrin from eukaryotic cells. This full-length protein binds
ATP/dATP and can be specifically eluted from ATP-agarose.
Intact nucleotide-binding capacity of cryopyrin is required for an
array of functions attributed to this protein.
Results
Recombinant Cryopyrin Can Be Purified to Homogeneity by Sequential
Affinity Chromatography. Studies of the nucleotide binding prop-
erties of cryopyrin (and other NBD-LRR proteins in plants and
animals) have been hampered by the fact that overexpressed,
full-length NBD-LRR proteins are largely insoluble. A dual-
tagged recombinant cryopyrin with an N-terminal hexahistidine
tag and a C-terminal FLAG tag was prepared in a baculoviral
expression system (Fig. 1A). A portion of the cryopyrin ex-
pressed in baculovirus-infected Hi5 cells is found in the soluble
fraction (Fig. 1B). Although this recombinant protein was
significantly enriched with nickel and anion-exchange chroma-
tography, a homogenous product was not achieved [supporting
information (SI) Fig. 7A, WT lanes]. Ultimately, soluble recom-
binant cryopyrin was purified to homogeneity (with a yield of
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10–20 g per liter of cell culture) by immobilized nickel
chromatography followed by an anti-FLAG immunoaffinity
chromatography (Fig. 1C). The purified protein was immuno-
reactive with antibodies directed toward the C-terminal FLAG
and N-terminal hexahistidine tags (Fig. 1C).
Cryopyrin Binds ATP and Exhibits ATPase Activity. Protein eluted
from immobilized nickel and anti-FLAG agarose each contained
binding activity for ATPS, a nonhydrolyzable ATP analog.
There was nucleotide-binding activity detected in preparations
of cryopyrin isolated by immobilized nickel chromatography.
This activity was further enriched 6-fold by anti-FLAG affinity
chromatography (Fig. 2A). Based on the amount of ATP S
bound, the stoichiometry of ATP S to purified cryopyrin under
these conditions is 1:3 (Fig. 2 A). Although this stoichiometry
is somewhat low, there are no other proteins observed in the
preparations with sufficient abundance to account for this
quantity of nucleotide binding. It is possible that purified
cryopyrin requires a nucleotide exchange factor to facilitate
stoichiometric ATP binding or that the some of the cryopyrin in
the preparation is soluble but inactive.
The ATP-binding activity of cryopyrin was further demon-
strated by association of cryopyrin with ATP-agarose or agarose
and elution of the protein with ATP-containing buffer (Fig. 2B).
The combination of measurable ATP binding in the preparation
of purified cryopyrin and preferential binding of the protein to
ATP-agarose indicates that cryopyrin is indeed an ATP-binding
protein. Purified cryopyrin also exhibited ATPase activity, as
shown by the release of 32P-PO4 from [-32P]ATP incubated with
cryopyrin (Fig. 2C). Thus, highly purified, recombinant
cryopyrin has both ATP-binding and hydrolysis activity.
The nucleotide-binding specificity of cryopyrin was assessed
by competition for ATP S binding activity by recombinant
cryopyrin with various unlabeled nucleotides. ATP competed for
ATP S binding by partially purified cryopyrin with an IC50 of
96 nM, 1,000-fold lower concentrations than the IC50 for GTP,
CTP, or UTP (Fig. 2D). Additionally, cryopyrin had a marked
preference for ATP and ATP S over ADP but showed no
significant difference between ATP and dATP (Fig. 2E). These
studies conclusively demonstrate that cryopyrin is an adenine
nucleotide-binding protein.
Mutation of the Walker A Motif of Cryopyrin Disrupts ATP Binding. All
CLR proteins are characterized by a predicted NBD contained
within an expanded region of 12 conserved elements (1). Among
these, the consensus Walker A motif contains the sequence
GKS/T, which correlates to G231, K232, and T233 of cryopyrin. The
lysine is involved in coordinating the -phosphate of ATP in
many proteins with this motif (20). All three of these residues
were mutated to alanine to generate the Walker A mutant (Fig.
3A). WT and Walker A mutant cryopyrin were expressed and
partially purified by using NiNTA agarose and anion-exchange
chromatography (SI Fig. 7A) or purified to homogeneity by using
sequential affinity chromatography as described earlier (Fig.
3B). WT and Walker A mutant cryopyrin were assayed for ATP
S binding at various stages of purification. Although the Walker
A mutant exhibited nearly identical solubility and chromato-
graphic properties, the detectable ATP S binding activity of a
partially purified preparation of cryopyrin (SI Fig. 7B) or of a
purified preparation of cryopyrin was extinguished by the mu-
tation (Fig. 3C).
An Intact NBD Is Required for Cryopyrin-Induced IL-1 Production. To
determine whether ATP binding is required for cryopyrin-
mediated IL-1 secretion in a biologically relevant cell type, the
human myeloid–monocytic cell line THP1 was transduced with
recombinant retrovirus expressing WT and Walker A mutant
cryopyrin. The recombinant retrovirus also expressed the gene
encoding GFP, which was used to identify transduced cells (21).
Cells transduced with WT cryopyrin demonstrated increased
IL-1 secretion when compared with retrovirus expressing only
GFP (empty vector) or the Walker A mutant (WA) (Fig. 4A).
When IL-1 production was corrected for the number of cells
that expressed GFP (Fig. 4B), the same trend was observed.
Levels of caspase-1 activation in retrovirally transduced cells
mirrored the findings with IL-1, suggesting the reduced levels
of IL-1 observed with expression of the Walker A mutant
cryopyrin were the result of a failure in caspase-1 activation by
that protein (Fig. 4C). Differences between the effects of
expression of WT and Walker A mutant cryopyrin are not
attributable to lower viral transduction efficiency (assayed by
flow cytometry) or cryopyrin expression (assayed by immuno-
blot analysis) (Fig. 4 D and E). Results from our current study
differ from other published studies in which THP-1 cells trans-
fected with plasmids that express WT cryopyrin do not sponta-
neously secrete IL-1 (22). Our results may reflect either higher
levels of expression or greater efficiency of transduction asso-
ciated with the use of spinoculation with recombinant retrovirus.
Fig. 1. Recombinant cryopyrin expressed in insect cell culture can be purified to homogeneity by affinity chromatography. (A) Schematic of the recombinant
tags on dual-tagged cryopyrin. N-terminal hexahistidine tag and TEV protease site and C-terminal FLAG tag are indicated. The Pyrin domain, NBD, and LRR
domains indicate domains of the native protein. (B) Dual-tagged cryopyrin was expressed in Hi5 Insect cells by infection with recombinant baculovirus
(multiplicity of infection  0.5). After the indicated times, the cells were harvested, flash-frozen, resuspended in lysis buffer, and sonicated. After centrifugation
at 15,000  g for 1 h, the supernatants (S, soluble fraction) were removed and the pellets (P, insoluble fraction) were resuspended in an equal volume of 1
SDS/PAGE loading buffer. The soluble (S, supernatant) and insoluble (P, pellet) fractions (Left) were subjected to immunoblot analysis with anti-FLAG antibody.
The soluble lysates from the infected cells fractions are run alone (Right) and demonstrate that immunoreactive material in the second lane in Left is not
bleed-over from a neighboring lane. (C) Recombinant cryopyrin was purified by sequential affinity chromatography. Protein eluted from the nickel (N, 200 ng)
followed by the anti-FLAG (F, 50 ng) columns were subjected to silver staining (Left) or immunoblot with indicated antibodies (Center and Right).
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Alternatively, spinoculation with recombinant virus may serve as
a weak inflammasome-assembly triggering stimulus that can
activate cells overexpressing cryopyrin but not those transduced
with empty virus. We have observed a lack of spontaneous IL-1
secretion after transfection of plasmids encoding WT cryopyrin
(Fig. 5C) just as reported by other groups (22). We have also used
recombinant retrovirus to transduce CIAS1/ mouse macro-
phages, although with a much lower efficiency of transduction.
In these experiments, WT cryopyrin expression restored both
LPS- and R838-induced IL-1 secretion whereas expression of
the Walker A mutant did not (data not shown). Thus, the Walker
A mutation eliminates spontaneous IL-1 production associated
with high levels of cryopyrin overexpression and regulated IL-1
production. These findings indicate that nucleotide binding is an
important step in cryopyrin-mediated caspase-1 and IL-1
production.
Gain of Function by Cryopyrin Disease-Associated Mutants Depends
on ATP Binding. CIAS1-associated fever syndromes are autosomal
dominant in inheritance, and disease-related cryopyrin mutants
lead to constitutive IL-1 production, suggesting that these muta-
tions lead to a constitutively activated cryopyrin molecule. Disease-
associated CIAS1 mutations are concentrated in the exon that
encodes the NBD. It was unknown whether such mutations pro-
mote constitutive activation of cryopyrin by circumventing the
requirement for nucleotide binding. We tested this by assessing the
role of nucleotide binding in the in vivo function of disease-
associated cryopyrin. The FCAS-associated A439V mutation was
Fig. 2. Recombinant cryopyrin is an ATP-binding protein. (A) ATP S binding
activity of the eluted fractions was assayed by filter binding assay as described
in SI Materials and Methods using 200 nM ATP S. (B) WT cryopyrin eluted
from NiNTA agarose was incubated with control or ATP-conjugated agarose.
Specific ATP-binding proteins were eluted by incubation with ATP-containing
buffer and analyzed by immunoblot with anti-FLAG antibody. (C) PO4 release
from [-32P]ATP in the presence of highly purified cryopyrin (see Fig. 1C) was
measured as described in SI Materials and Methods. Error bars indicate
standard deviation of triplicate samples. (D and E) NiNTA and anion-exchange
chromatography-enriched cryopyrin was used to assess the specificity of
cryopyrin-associated nucleotide-binding activity. Cryopyrin was incubated
with 2 nM 35S-ATP S (10,000 cpm/pmol) and the indicated concentration of
unlabeled competitor nucleotides at 4°C for 30 min (at which time bound
nucleotide was increasing linearly with increasing time), and bound ATP S
was assayed. Curves represent nonlinear regression fit to single-site compe-
tition model (Y  100/(1  10(X-Log(EC50)))).
Fig. 3. Mutation of the Walker A motif of cryopyrin abrogates its ATP-
binding activity. (A) WT and Walker A mutant variants of cryopyrin. Mutated
Walker A sequence is shown. Walker B mutation, used in SI Table 1, is noted.
Disease-associated mutations, R260W and A439V, used in Fig. 5, are also
noted. (B) WT and Walker A mutant (WA) cryopyrin were purified by sequen-
tial affinity chromatography as described in Fig. 1A. Silver staining (Left) and
immunoblot analysis (Right) of 50 ng of each of the purified proteins is shown.
(C) ATP S binding activity of the indicated proteins was assayed at 60 min in
the presence of 200 nM ATP S. Error bars represent standard deviation of
ATP-binding measurements determined in triplicate.
Fig. 4. ATP binding by cryopyrin is essential for cryopyrin-induced IL-1
production. THP1 cells were transduced with recombinant retrovirus express-
ing the following proteins: empty vector (EV), no cryopyrin; WT cryopyrin; and
Walker A mutant (WA) cryopyrin. (A) IL-1 secretion was measured 24 h after
transduction by ELISA. (B) IL-1 measured in A was corrected for the number
of GFP cells in the culture. (C) Secreted caspase-1 was assayed by ELISA. Error
bars represent standard deviation between transductions performed in trip-
licate. (D) Retroviral transduction efficiency was determined by monitoring
GFP expression with flow cytometry. (A–D) Error bars represent standard
deviation between transductions performed in triplicate. (E) Expression levels
of recombinant cryopyrin were assessed by immunoblot analysis with anti-
FLAG antibody.









introduced into the Walker A mutant cDNA and designated as the
A439V/WA double mutant (Fig. 5A). The A439V disease-
associated mutant induced significantly more IL-1 secretion when
compared with the WT control, consistent with previous reports
(Fig. 5A) (13, 22). However, IL-1 production was absent in cells
expressing the A439V/Walker A double-mutant molecules (Fig.
5A). Correction for the number of GFP-expressing cells in each
culture yielded the same findings (Fig. 5B). This establishes that a
disease-associated form of cryopyrin still requires nucleotide bind-
ing for its activation. To determine whether this finding could be
extended to other disease-associated cryopyrin mutants, we tested
the FCAS/Muckle–Wells syndrome-associated R260W mutant.
THP1 cells transfected with plasmids encoding this mutant pro-
duced more IL-1 than those expressing the WT control, but
mutations in the Walker A (labeled R260W/WA; see Fig. 3A for
mutations) ablated IL-1 production (Fig. 5C). Combined, these
findings suggest that therapies directed at nucleotide binding by
cryopyrin represent a viable strategy to modulate the function of
periodic fever-associated mutant proteins. This may be especially
appealing for long-term control of these diseases where an oral
agent might be preferable to current injectable anti-IL-1 therapies.
Overexpression of WT cryopyrin has been shown to cause an
ASC1-dependent cell death (14). More recently, periodic fever-
associated mutant cryopyrin expression has been shown to
induce necrotic cell death (15). A reduction in viable cells was
also observed when THP1 cells were transduced with retrovirus
or adenovirus expressing the disease-associated mutant
cryopyrins (SI Fig. 8 B and C). These constructs caused more
IL-1 secretion as expected (SI Fig. 8A). The cell death asso-
ciated with two disease-associated cryopyrin mutants also de-
pends on functional ATP-binding activity (SI Fig. 8 B and C).
The physiologic significance of cryopyrin-induced cell death
remains to be determined; however, our data indicate that both
the cell death-inducing and IL-1-producing activities of
cryopyrin require intact ATP binding by the protein.
Intact Nucleotide Binding Is Required for the Self-Association of
Cryopyrin. Binding of dATP by Apaf-1 is a critical step in the
assembly of the apoptosome (23). It has been hypothesized that
CATERPILLER proteins require nucleotide binding to form a
macromolecular complex and activate their respective signaling
pathways. To determine whether ATP binding by cryopyrin
affected complex formation, soluble fractions from HEK293
cells expressing either WT cryopyrin or the Walker A mutant
were subjected to gel filtration chromatography. These cells were
used initially because protein expression in THP1 cells was low.
Immunoblot analysis revealed that the WT cryopyrin protein
was found predominantly in fractions approaching 1,000 kDa
(Fig. 6A Upper), while the mutant protein ran between 200 and
600 kDa (Fig. 6A Lower). This size difference could reflect either
self-association or assembly with other proteins by the WT
protein. Because HEK293 cells do not secrete IL-1 and lack
other known inflammasome components, it is more likely that
the Walker A mutation blocked both ATP binding and self-
association of the protein. To test this hypothesis, a bidirectional
self-association analysis was performed by transfection of HA-
tagged and FLAG-tagged cryopyrin followed by immunopre-
cipitation with either anti-HA or anti-FLAG antibodies and
immunoblot analysis directed against the other tag. Whereas the
WT cryopyrin protein was found to self-associate, the Walker A
mutant protein associated less efficiently with coexpressed WT
cryopyrin (Fig. 6B). CIITA, an NBD-LRR containing protein,
did not associate with cryopyrin. Thus, an intact NBD is neces-
sary for the specific self-association of cryopyrin.
Intact Nucleotide Binding Regulates the Association of Cryopyrin with
ASC. Cryopyrin has been proposed to form a caspase-1 activating
structure called the inflammasome, which contains cryopyrin,
ASC, and CARDINAL (13). We sought to determine whether
assembly of the cryopyrin-containing inflammasome depends on
nucleotide binding by cryopyrin in THP1 cells, which express
endogenous cryopyrin. Cryopyrin was isolated by immunopre-
cipitation with anti-FLAG antibody from cytosolic extracts of
THP1 cells expressing the WT or Walker A mutant cryopyrin
molecules and analyzed for their association with endogenous
ASC. Coimmunoprecipitation of ASC with cryopyrin was dras-
tically reduced with the Walker A mutant when compared with
the WT protein (Fig. 6C), suggesting that cryopyrin requires
binding of ATP to associate with ASC.
Discussion
This work shows that highly purified, recombinant full-length
cryopyrin isolated from eukaryotic cells binds to and hydrolyzes
ATP. Nucleotide binding is further demonstrated by mutagen-
esis, nucleotide competition, binding to ATP-agarose, and elu-
tion by ATP. Analysis of mutant cryopyrin lacking this activity
indicates that ATP binding by cryopyrin is essential to a host of
cryopyrin-mediated functions. Similar elimination of biological
function of other CLR genes and plant R genes has been
reported with mutation of the Walker A domain in the respective
systems (18, 24–26). Our current data cannot distinguish be-
tween the possibility that nucleotide binding by cryopyrin is a
regulated process controlling signal transduction by the protein
or that nucleotide binding is required for proper folding or to
stabilize a signaling competent protein but is not regulated
during inflammasome assembly by the protein.
Studies of the mechanism of Apaf-1 and apoptosome assembly
and the function of some plant R proteins suggest that nucleotide
Fig. 5. Constitutive activity of disease-associated mutant cryopyrin requires intact ATP-binding activity. (A and B) THP1 cells were transduced with recombinant
retrovirus expressing the following proteins: empty vector (EV), no cryopyrin; WT cryopyrin; Walker A mutant (WA) cryopyrin; FCAS mutant cryopyrin (A439V);
and FCAS mutant cryopyrin with Walker A mutation (A439V/WA). (A) IL-1 secretion was measured 12 h after transduction by ELISA. (B) IL-1 measured in A was
corrected for the number of GFP cells in the culture. Error bars represent standard deviation between transductions performed in triplicate. (C) THP1 cells were
transfected with plasmids expressing GFP and the following proteins: empty vector (EV), no additional protein; WT cryopyrin; FCAS/Muckle–Wells syndrome
mutant cryopyrin (R260W); and R260W with Walker A mutation (R260W/WA). Secreted IL-1 was assayed by ELISA 24 h after transfection. Error bars represent
standard error from duplicate measurements.
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binding by cryopyrin is likely to be a regulated process control-
ling inf lammasome assembly. Although Apaf-1-stimulated
caspase-3 activation is not supported by nonhydrolyzable ATP or
dATP analogs, suggesting a role for ATP hydrolysis in this
process, the role of ATP hydrolysis in inflammasome assembly
or disassembly remains to be characterized. Mutations in the
plant R protein i-2, which confer constitutive activation of its
signaling pathway, have been found to not hydrolyze ATP,
suggesting that some human CATEPILLER proteins may also
be bound to ATP during their active stage (25). Studies of
inflammasome assembly using purified components, including
cryopyrin, and defined nucleotides, including nonhydrolyzable
analogs, are obvious extensions of this work to examine this
problem.
We have also demonstrated that the disease-associated phe-
notype of mutant cryopyrin requires ATP binding. Using the
model of regulated nucleotide binding controlling inflamma-
some assembly, our data imply that these mutations of cryopyrin
are likely to promote ADP/ATP exchange, inhibit ATPase
activity of the protein, or otherwise facilitate ATP binding and
activation of the protein. Mutations that lead to constitutive
activation of guanine nucleotide-binding proteins (G proteins)
have been associated with loss of GTPase activity (locking the
protein in GTP bound state) or with decreased GDP affinity
(leading to increased GTP for GDP nucleotide exchange) (27,
28). Before this work, the enhanced activity of disease-associated
mutants could have been attributed to an unregulated, ATP-
independent activation of the protein or to a novel activity of the
mutant protein not ascribable to the WT cryopyrin. This work
indicates that the function of disease-associated cryopyrin pro-
teins is still ATP-dependent. Determination of the molecular
mechanism underlying the constitutive activity of these mutant
proteins will rely on detailed biochemical analysis of their
ATP-binding properties. However, disease-associated mutants
are even more difficult to enrich and purify (data not shown);
thus, improvements in the expression system will need to be
made to undertake these studies.
This study serves as a proof-of-principle that disease-
associated activation of cryopyrin signaling can be modulated by
interference with the nucleotide binding of this protein. Nucle-
otide analogs with specificity for nucleotide using enzymes
associated with specific diseases are currently used in a number
of clinical settings. A prime example is the use of nucleotide
analogs for the treatment of HIV (29). A pyrimidine-derived
inhibitor of the BCR-ABL kinase, imatinib, has also proven
successful for treating chronic myelogenous leukemia (30). In
the future, cryopyrin-binding nucleotide analogs might have use
in the treatment of hereditary inflammatory syndromes as well
as other inflammatory conditions that use cryopyrin-mediated
signaling.
Materials and Methods
Construction of CIAS1 Expression Plasmids. Standard techniques of
DNA manipulation were used (31). Details of cloning strategies
and oligonucleotide sequences used are provided in SI Materials
and Methods.
Cell Culture and Transfection. THP1 and HEK293 (American Type
Culture Collection, Manassas, VA) were cultured under recom-
Fig. 6. Cryopyrin self-association and association with ASC require ATP binding. (A) Extracts from HEK293 cells transfected with plasmids encoding FLAG-tagged
WT (Upper) or Walker A mutant (Lower) versions of cryopyrin were subjected to size-exclusion chromatography (as detailed in Materials and Methods). The
chromatograms show UV absorbance plotted against volume of elution. Arrows indicate volume of elution for standards of the indicated molecular mass.
Cryopyrin content (shown below the chromatographs) is determined by immunoblot analysis with anti-FLAG antibodies. (B) HEK293 cells were transfected with
indicated plasmids. Lysates from the cells were subjected to immunoprecipitation with anti-HA antibodies (Left) and anti-FLAG antibodies (Right), and samples
were analyzed by immunoblot analysis with the indicated antibodies. (C) THP1 cells were transduced with recombinant retrovirus expressing the following
proteins: empty vector, no cryopyrin; FLAG-tagged cryopyrin; or Walker A mutant (WA) FLAG-tagged cryopyrin. Cell lysates were subjected to immunoprecipi-
tation with anti-FLAG antibody and analyzed by immunoblot with anti-FLAG and anti-ASC. The second and fourth lanes in Left have no sample.









mended conditions. FuGENE 6 transfection reagent (Roche,
Indianapolis, IN) was used for transfection of HEK293 cells.
Immunoprecipitation and Immunoblot Analysis. Immunoprecipita-
tions were carried out in 50 mM TrisHCl (pH 8.0), 150 mM
NaCl, 1 mM MgCl2, and 0.5% Nonidet P-40 supplemented with
complete protease inhibitor mixture (Roche) and 1 mM ATP.
Lysates from 5  107 cells were incubated for 30 min at 30°C
before immunoprecipitation with agarose-conjugated anti-
FLAG (M2) or anti-HA (12CA5) antibodies (Sigma–Aldrich, St.
Louis, MO) followed by SDS/PAGE. Anti-hexahistidine anti-
body (His Probe, H3) was from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-ASC antibody (AL177) was from Alexis
Biochemicals (Lausen, Switzerland).
Expression of Recombinant Cryopyrins in THP1 Cells. Recombinant
retrovirus expressing cryopyrin and mutant variants was gener-
ated as described by Coffield et al. (21). Recombinant adeno-
virus was generated by using the AdenoX system (BD Biosys-
tems, Franklin Lakes, NJ). THP1 cells were virally transduced by
using a ‘‘spinoculation’’ protocol. Details are provided in SI
Materials and Methods. Transfection of plasmids encoding
cryopyrin and mutant variants into THP1 cells was carried out
by using the Nucleofector V kit (Amaxa, Gaithersburg, MD)
according to the manufacturer’s protocol.
Flow Cytometry and ELISA. Annexin V-PE (BD Biosciences) was
used according to the manufacturer’s protocols. Flow cytometry
was performed on a FACScan instrument (BD Biosciences). An
OptEIA human IL-1 ELISA kit (BD Biosciences) was used for
secreted IL-1 quantitation. Secreted caspase-1 was detected by
using a caspase-1 ELISA kit (Alexis Biochemicals).
Baculovirus and Insect Cell Culture. Recombinant baculovirus ex-
pressing cryopyrin was generated by using the Bac to Bac system
(Invitrogen, Carlsbad, CA). Insect cell culture and baculovirus
infection were performed according to the manufacturer.
Purification of Recombinant Cryopyrin. Frozen Hi5 cells were lysed
by sonication, and recombinant proteins were purified by using
NiNTA agarose (Qiagen, Valencia, CA) and agarose-conjugated
anti-FLAG (M2) antibody (Sigma–Aldrich) using modified man-
ufacturers’ protocols. Anion-exchange chromatography was per-
formed by using a Duoflow chromatography system (Bio-Rad,
Hercules, CA). Details are provided in SI Materials and Methods.
ATP S Binding and ATP Hydrolysis Assays. Nucleotide binding was
assayed by using a nitrocellulose filter binding assay (32).
Nucleotide hydrolysis assays were carried out by using a modified
acidified charcoal precipitation (33). Further details are pro-
vided in SI Materials and Methods.
Gel Filtration Chromatography. Soluble lysates from cultured cells
were prepared by hypotonic lysis (buffer is described in SI
Materials and Methods) and shearing through a 27-gauge needle.
Soluble lysate (0.5 mg of total protein) was run on a Biosil 400
gel filtration column using a Bio-Rad Duoflow chromatography
system in PBS with 2 mM DTT.
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